The impact of immunomodulation on host response and microbiota evolution

• Author(s): Silva, Catarina ; Melo-Miranda, Rita ; Almeida, Catarina R. ; Sousa, Ana Margarida
• Date: 2023
• Persistent ID: http://hdl.handle.net/10773/41261
• Origin: RIA - Repositório Institucional da Universidade de Aveiro
• Document Type: Conference object
• Language: English

Description

The interplay between gut microbiota and the host is important for immunity development, colonization resistance and host metabolism. Antibiotic use disrupts host-microbiota interactions, potentially decreasing the colonization resistance conferred by the gut microbiota. Lipopolysaccharide (LPS), an endotoxin present in Gram-negative bacteria, induces potent acute systemic inflammation. Nevertheless, it has also been suggested that treatment with low-dose LPS in a continuous manner, can act as an immunomodulator, conferring protective effects against infection. Additionally, the production of antimicrobial peptides (AMPs) impaired by the antibiotic treatment was previously observed to be restored upon LPS administration and therefore thought to be implicated in LPS protective effect. However, little is known about how immunomodulation (with low-dose LPS) impacts colonization resistance to non-pathogenic bacteria or how commensal microbiota evolve in an environment where the innate immune response is strengthened. To answer these questions, mice were treated with streptomycin, previously reported to induce gut inflammation, and then colonized with a commensal strain of Escherichia coli by oral gavage. To test the impact of immunomodulation, LPS was administered to half of the animals prior to antibiotic treatment and gut colonization. Immunomodulation by LPS led to a decreased production of TNF-α and IFN-γ when comparing with antibiotic treatment alone. Furthermore, LPS animals showed reduced gut damage as observed in the histopathological analysis and permeability assays. Additionally, LPS treatment delayed the colonization by E. coli in the gut as shown by the decreased count of CFUs. Our on-going project will evaluate how LPS treatment affects AMP expression and microbiota evolution. We expect to uncover distinctive adaptive signatures between LPS-treated and control mice, thus enhancing our understanding of the role of LPS in shaping microbiota and immunity.